A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease

References

• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine27(Suppl. 2), B51–B63 (2009).
   PubMed Web of Science ®Google Scholar
• Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J. Immunol.138(12), 4402–4407 (1987).
   PubMed Web of Science ®Google Scholar
• Hayrinen J, Jennings H, Raff HV et al. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J. Infect. Dis.171(6), 1481–1490 (1995).
   PubMed Web of Science ®Google Scholar
• Devoe IW, Gilchrist JE. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J. Exp. Med.138(5), 1156–1167 (1973).
   PubMed Web of Science ®Google Scholar
• Lewis S, Sadarangani M, Hoe JC, Pollard AJ. Challenges and progress in the development of a serogroup B meningococcal vaccine. Expert Rev. Vaccines8(6), 729–745 (2009).
   PubMed Web of Science ®Google Scholar
• Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14(2), 67–79; discussion 79–80 (1991).
   PubMedGoogle Scholar
• Granoff DM. Review of meningococcal group B vaccines. Clin. Infect. Dis.50(Suppl. 2), S54–S65 (2010).
   PubMed Web of Science ®Google Scholar
• Rodriguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem. Inst. Oswaldo Cruz94(4), 433–440 (1999).
   PubMed Web of Science ®Google Scholar
• Bjune G, Gronnesby JK, Hoiby EA, Closs O, Nokleby H. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann.14(2), 125–130; discussion 130–122 (1991).
   PubMedGoogle Scholar
• Taha MK, Zarantonelli ML, Alonso JM et al. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine25(14), 2537–2538 (2007).
   PubMed Web of Science ®Google Scholar
• Galloway Y, Stehr-Green P, McNicholas A, O’Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol.38(2), 413–418 (2009).
   PubMed Web of Science ®Google Scholar
• Martin DR, Ruijne N, McCallum L, O’Hallahan J, Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol.13(4), 486–491 (2006).
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Wong SH, Lennon DR, Jackson CM et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr. Infect. Dis. J.28(5), 385–390 (2009).
   PubMed Web of Science ®Google Scholar
• Tondella ML, Popovic T, Rosenstein NE et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J. Clin. Microbiol.38(9), 3323–3328 (2000).
   PubMed Web of Science ®Google Scholar
• Gray SJ, Trotter CL, Ramsay ME et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol.55(Pt 7), 887–896 (2006).
   PubMed Web of Science ®Google Scholar
• Oster P, O’Hallahan J, Aaberge I et al. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine25(16), 3075–3079 (2007).
   PubMed Web of Science ®Google Scholar
• van der Ley P, Poolman JT. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun.60(8), 3156–3161 (1992).
   PubMed Web of Science ®Google Scholar
• Claassen I, Meylis J, van der Ley P et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine14(10), 1001–1008 (1996).
   PubMed Web of Science ®Google Scholar
• van den Dobbelsteen G, van Dijken H, Hamstra H et al. From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine. Programs and Abstracts of the 14th International Pathogenic Neisseria Conference. Milwaukee, WI, USA (2004) (Abstract P153).
   Google Scholar
• Boutriau D, Poolman J, Borrow R et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol.14(1), 65–73 (2007).
   PubMed Web of Science ®Google Scholar
• Gorringe A, Halliwell D, Matheson M et al. The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Vaccine23(17–18), 2210–2213 (2005).
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Taylor S, Brookes C et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin. Vaccine Immunol.16(8), 1113–1120 (2009).
   PubMedGoogle Scholar
• Keiser PB, Biggs-Cicatelli S, Moran EE et al. A Phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine29(7), 1413–1420 (2011).
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol.177(1), 501–510 (2006).
   PubMed Web of Science ®Google Scholar
• Masignani V, Comanducci M, Giuliani MM et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med.197(6), 789–799 (2003).
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun.72(4), 2088–2100 (2004).
   PubMed Web of Science ®Google Scholar
• Pizza M, Donnelly J, Rappuoli R. Factor H-binding protein, a unique meningococcal vaccine antigen. Vaccine26(Suppl. 8), I46–I48 (2008).
   PubMedGoogle Scholar
• Walport MJ. Complement. First of two parts. N. Engl. J. Med.344(14), 1058–1066 (2001).
   PubMed Web of Science ®Google Scholar
• Schneider MC, Exley RM, Chan H et al. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol.176(12), 7566–7575 (2006).
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Meningococcal biology and vaccines: ten years of genomics and reverse vaccinology. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada (2010) (Abstract VW02).
   Google Scholar
• Beernink PT, Welsch JA, Harrison LH et al. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J. Infect. Dis.195(10), 1472–1479 (2007).
   PubMed Web of Science ®Google Scholar
• Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine28(9), 2122–2129 (2010).
   PubMed Web of Science ®Google Scholar
• Bambini S, Muzzi A, Olcen P et al. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine27(21), 2794–2803 (2009).
   PubMed Web of Science ®Google Scholar
• Beernink PT, Leipus A, Granoff DM. Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin. Vaccine Immunol.13(7), 758–763 (2006).
   PubMedGoogle Scholar
• Lucidarme J, Comanducci M, Findlow J et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin. Vaccine Immunol.17(6), 919–929 (2010).
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine28(37), 6086–6093 (2010).
   PubMed Web of Science ®Google Scholar
• McNeil LK, Murphy E, Zhao XJ et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine27(25–26), 3417–3421 (2009).
   PubMed Web of Science ®Google Scholar
• Richmond P, Marshall H, Sheldon E et al. Safety & immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada (2010) (Abstract VW04).
   Google Scholar
• Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science287(5459), 1816–1820 (2000).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA103(29), 10834–10839 (2006).
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Brunelli B et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med.195(11), 1445–1454 (2002).
   PubMed Web of Science ®Google Scholar
• Capecchi B, Adu-Bobie J, Di Marcello F et al.Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol. Microbiol.55(3), 687–698 (2005).
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Caugant DA et al. NadA diversity and carriage in Neisseria meningitidis. Infect. Immun.72(7), 4217–4223 (2004).
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Comanducci M, Findlow J et al. Characterisation of fHbp, nhba (gna2132), nadA, porA, sequence type and the genomic presence of IS1301 in group B meningococcal ST269 clonal complex case-isolates from England and Wales. J. Clin. Microbiol.47(11), 3577–3585 (2009).
   PubMed Web of Science ®Google Scholar
• Serruto D, Spadafina T, Ciucchi L et al.Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc. Natl Acad. Sci. USA107(8), 3770–3775 (2010).
   PubMed Web of Science ®Google Scholar
• Welsch JA, Moe GR, Rossi R et al. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J. Infect. Dis.188(11), 1730–1740 (2003).
   PubMed Web of Science ®Google Scholar
• Holst J, Bambine S, Muzzi A et al. Sequence variation and degree of expression for five genome-derived vaccine antigens included in the MenB Novartis investigational vaccine. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada (2010) (Abstract P047).
   Google Scholar
• Wang X, Cohn A, Comanducci M et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada (2010) (Abstract P089).
   Google Scholar
• Snape MD, Dawson T, Oster P et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J.29(11), e71–e79 (2010).
   Web of Science ®Google Scholar
• Dull P, Kimura A, Vienken K et al. Phase III formulation development of recombinant meningococcal B vaccine (rMenB) containing fHbp, NHBA, NadA, and New Zealand (NZ98/254) outer membrane vesicles (OMV). Programs and Abstracts of the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases. Nice, France (2010) (Poster).
   Google Scholar
• Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin. Vaccine Immunol.18(3), 483–486 (2010).
   PubMedGoogle Scholar
• Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl Acad. Sci. USA107(45), 19490–19495 (2010).
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N et al.Neisseria meningitidis group B correlates of protection and assay standardization – international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine24(24), 5093–5107 (2006).
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD et al. Multicenter, open-label, randomized Phase II Controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis.51(10), 1127–1137 (2010).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Kimura A et al. Immunogenicity of an investigational multicomponent meningococcal serogroup B vaccine in healthy infants at 2, 4 and 6 months of age. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada (2010) (Abstract P180).
   Google Scholar
• Brunelli B, Del Tordello E, Palumbo E et al. Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1. Vaccine29(5), 1072–1081 (2011).
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Biolchi A, Serruto D et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine28(31), 5023–5030 (2010).
   PubMed Web of Science ®Google Scholar
• Biolchi A, Kleinschmidt A, Boccadifuoco G et al. Evaluation of the contribution of protein antigen NHBA to bactericidal antibody responses in sera from human vaccinees enrolled in clinical trials. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada (2010) (Abstract P188).
   Google Scholar
• Esposito S, Vesikari T, Kimura A et al. Tolerability of a three-dose schedule of an investigational, multicomponent meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada (2010) (Abstract P182).
   Google Scholar
• Brunelli B, Tordello E, Palumbo E et al. Evaluation of the cross protective capabilities of the Neisseria meningitidis fHbp antigen subvariant 1.1 through the generation of engineered meningococcal strains. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada (2010) (Abstract P205).
   Google Scholar
• Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl Acad. Sci. USA107(45), 19490–19495 (2010).
   PubMed Web of Science ®Google Scholar
• Plikaytis B, Stella M, Toti S et al. Interlaboratory standardization of the MATS ELISA: a protein antigen phenotyping method for N. meningitidis serogroup B. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada (2010) (Abstract P196).
   Google Scholar
• Claus H, Maiden MC, Wilson DJ et al. Genetic analysis of meningococci carried by children and young adults. J. Infect. Dis.191(8), 1263–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter C, Hickman M, Edmunds W. Modelling the cost–effectiveness of new meningococcal vaccines in England. Programs and Abstracts of the 17th International Pathogenic Neisseria Conference. Banff, Canada (2010) (Abstract OM08).
   Google Scholar